Kelly Michael Aaron 4
4 · NEOGENOMICS INC · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
NEOGENOMICS (NEO) Director Kelly Michael Aaron Receives/Exercises Shares
What Happened
- Director Kelly Michael Aaron reported conversion/exercise and award activity on June 1, 2026. The filing shows conversion/exercise (code M) of 23,077 shares at $0.00, a matching derivative disposal of 23,077 shares at $0.00, and two award/grant entries (code A) for 11,069 and 15,970 shares at $0.00. Gross shares acquired across the entries total 50,116 shares; the filing records a simultaneous disposal of 23,077 shares. All reported transactions have $0 total consideration.
Key Details
- Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (filed two days after the transactions).
- Reported prices: $0.00 for all entries; total cash exchanged reported = $0.
- Shares listed: Acquired = 23,077 (exercise/conversion) + 11,069 (award) + 15,970 (award) = 50,116; Disposed = 23,077.
- Shares owned after the transactions: not disclosed in the data provided.
- Footnotes: F1 — reflects release of restricted stock units (RSUs) previously reported on a Form 4. F2 — once vested, the shares of common stock are not subject to expiration.
- No 10b5-1 plan or late-filing flag noted in the provided data.
Context
- The entries are derivative-related (exercise/conversion and awards) and reflect issuance/release of previously granted RSUs or similar awards rather than an open-market buy or sale. A same-day "disposed" entry often appears alongside conversions to reflect share surrender/withholding, but the filing itself does not state the reason. These transactions are routine for vesting/settlement of equity awards and do not directly indicate a market-direction trade by the insider.
Insider Transaction Report
Form 4
Kelly Michael Aaron
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-01+23,077→ 67,086 total - Exercise/Conversion
Restricted Stock Unit
[F2]2026-06-01−23,077→ 0 totalExercise: $0.00From: 2026-06-01→ Common Stock (23,077 underlying) - Award
Stock Option (Right to Buy)
2026-06-01+11,069→ 11,069 totalExercise: $10.52From: 2027-06-01Exp: 2036-06-01→ Common Stock (11,069 underlying) - Award
Restricted Stock Unit
[F2]2026-06-01+15,970→ 15,970 totalExercise: $0.00From: 2027-06-01→ Common Stock (15,970 underlying)
Holdings
- 5,000(indirect: By Trust)
Common Stock
- 2,223
Stock Option (Right to Buy)
Exercise: $37.53From: 2021-05-28Exp: 2027-05-28→ Common Stock (2,223 underlying) - 3,714
Stock Option (Right to Buy)
Exercise: $40.90From: 2022-06-02Exp: 2028-06-02→ Common Stock (3,714 underlying) - 13,882
Stock Option (Right to Buy)
Exercise: $8.10From: 2023-06-10Exp: 2029-06-10→ Common Stock (13,882 underlying) - 8,353
Stock Option (Right to Buy)
Exercise: $14.82From: 2024-08-10Exp: 2033-08-10→ Common Stock (8,353 underlying) - 8,672
Stock Option (Right to Buy)
Exercise: $13.71From: 2025-06-01Exp: 2034-06-01→ Common Stock (8,672 underlying) - 16,107
Stock Option (Right to Buy)
Exercise: $7.28From: 2026-06-01Exp: 2035-06-01→ Common Stock (16,107 underlying)
Footnotes (2)
- [F1]Reflects release of restricted stock units that were previously reported on a Form 4.
- [F2]Once vested, the shares of common stock are not subject to expiration.
Signature
/s/ Ali Olivo, Attorney-in-Fact|2026-06-03